Merck & Company, Inc. · NYSE:MRK
Merck & — Investor Day (October 2023)
31 slides from Merck &'s investor day presentation, Oct 22, 2023
Slide 1: Daiichi Sankyo Collaboration and ESMO Investor Event
PRESENT Daiichi Sankyo Collaboration and ESMO Investor Event October 22, 2023
Slide 2: Forward-looking statement of Merck & Co., Inc.
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These state
Slide 3: Opening Remarks
Opening Remarks Dr. Dean Li President, Merck Research Laboratories
Slide 4: Agenda
Agenda Dr. Dean Li President, Merck Research Laboratories Opening Remarks | Dr. Dean Li Overview of Daiichi Sankyo Programs | Dr. Eliav Barr Dr. Eliav Barr SVP, Head of Global Key ESMO Data Presentation Highlights | Dr. Marjorie Green Clinical Development & Chief Medical Officer Closing Remarks | Dr
Slide 5: Continuing to advance our oncology strategy
Continuing to advance our oncology strategy Immuno-oncology Precision Molecular Tissue Targeting Boost anti-tumor Targeting Increase cancer cell immune responses Impact pathways that sensitivity with ADCs can drive cancer growth and immune-engagers 5
Slide 6: Science-driven collaboration to advance ADC innovation for patients
Science-driven collaboration to advance ADC innovation for patients Translating breakthrough science into treatments that save and improve the lives of patients • Committed to addressing the significant & remaining unmet patient need in oncology • Advancing 3 potentially first-in-class ADCs across a
Slide 7: Clinical Profile
Clinical Profile Dr. Eliav Barr SVP, Head of Global Clinical Development & Chief Medical Officer
Slide 8: Building on innovative pipeline and portfolio for sustained oncology leadership
Building on innovative pipeline and portfolio for sustained oncology leadership Immuno-oncology Precision Molecular Targeting Tissue Targeting Boost anti-tumor immune responses Impact pathways that can drive Increase cancer cell sensitivity cancer growth with ADCs and immune-engagers 2 3 favezelimab
Slide 9: Combining the unique strengths of Daiichi Sankyo and Merck
Combining the unique strengths of Daiichi Sankyo and Merck Daiichi Sankyo has a proven track record of Merck has a proven track record of oncology pioneering next-generation ADCs clinical development • Leverage clinical trial expertise and global scale to advance ADC programs Antibody • Foundational
Slide 10: Adding three potential first-in-class ADCs to our broad oncology pipeline
Adding three potential first-in-class ADCs to our broad oncology pipeline U3-1402 DS-7300 DS-6000 (HER3-DXd) (I-DXd) (R-DXd) Patritumab Ifinatamab Raludotatug Generic Name deruxtecan deruxtecan deruxtecan • Novel targets with encouraging data across several tumor types Target HER3 B7H3 CDH6 • Potent
Slide 11: Continuing to expand our presence in the ADC field
Continuing to expand our presence in the ADC field U3-1402 MK-2870 DS-7300 DS-6000 MK-1200 1 additional (HER3-DXd) (I-DXd) (R-DXd) clinical asset Daiichi Kelun Daiichi Daiichi Kelun Kelun Collaborator Sankyo Biotech Sankyo Sankyo Biotech Biotech Patritumab Sacituzumab Ifinatamab Raludotatug Generic
Slide 12: Key Data Highlights
Key Data Highlights Dr. Marjorie Green SVP, Head of Late Oncology Development
Slide 13: Highlighting progress across our oncology program at ESMO
Highlighting progress across our oncology program at ESMO Merck data presentations at ESMO 2023 Aligns with structured approach to oncology development program 4 Approved medicines 3 Pipeline candidates >15 Types of cancer 13
Slide 14: Phase 3 data presentations
INVENTING FOR LIFE Phase 3 data presentations
Slide 15: KEYNOTE-671 demonstrates potential for KEYTRUDA as perioperative treatment
KEYNOTE-671 demonstrates the potential for KEYTRUDA as perioperative treatment to extend the lives of patients with earlier stage NSCLC Overall survival • Neoadjuvant KEYTRUDA plus chemotherapy followed by resection and adjuvant KEYTRUDA reduced the risk of death by 28% in patients with resectable s
Slide 16: Potential practice changing KEYNOTE-A39 results in urothelial cancers
Potential practice changing KEYNOTE-A39 results: significant improvement in outcomes for patients with certain urothelial cancers Overall survival • KEYTRUDA in combination with enfortumab vedotin reduced the risk of death by 53% in both cisplatin eligible and ineligible patients with previously unt
Slide 17: Advancing KEYTRUDA-based regimens in earlier stages of women's cancers
Advancing KEYTRUDA-based regimens to improve outcomes in earlier stages of women’s cancers KEYNOTE-A18: Cervical cancer KEYNOTE-756: ER+/ HER2- breast KEYNOTE-522: TNBC cancer +XX% YOY Data cutoff date: January 9, 2023. Data cutoff date: March 23, 2023. Data cutoff date: March 23, 2023. • Pembrolizu
Slide 18: LITESPARK-005 first positive Phase 3 study in advanced kidney cancer
LITESPARK-005 is first positive Phase 3 study in patients with advanced kidney cancer following immune checkpoint and anti-angiogenic therapies Progression-free survival • Belzutifan reduced the risk of disease progression or death by 26% compared to everolimus • 22.7% of patients had an ORR while o
Slide 19: Pipeline advancements
INVENTING FOR LIFE Pipeline advancements
Slide 20: Promising Phase 1/2 data for MK-2870 in HR+/HER2- breast cancer
Promising Phase 1/2 data for MK-2870 demonstrates potential in HR+/HER2-negative metastatic breast cancer Best change from baseline in sum of target lesions per • MK-2870 demonstrated encouraging anti-tumor investigator assessment activity in patients with HR+/HER2- metastatic breast cancer − Object
Slide 21: MK-1084, a KRAS G12C inhibitor, shows promising Phase 1 results
MK-1084, a KRAS G12C inhibitor, shows promising Phase 1 results that build on the foundation of KEYTRUDA Objective response rate • MK-1084 provides promising evidence of anti-tumor activity in patients with previously treated solid malignancies and in combination with pembrolizumab in previously unt
Slide 22: Closing Remarks
Closing Remarks Dr. Dean Li President, Merck Research Laboratories
Slide 23: Demonstrating ongoing clinical benefit for patients across oncology portfolio
Demonstrating ongoing clinical benefit for patients across oncology portfolio Immuno-oncology Precision Molecular Targeting Tissue Targeting Boost anti-tumor immune responses Impact pathways that can drive Increase cancer cell sensitivity cancer growth with ADCs and immune-engagers 2 3 favezelimab/p
Slide 24: Q&A
Q&A Dr. Dean Li Dr. Eliav Barr Dr. Marjorie Green Jannie Oosthuizen President, SVP, Head of Global SVP, Head of Late President, Merck Research Clinical Development & Oncology Development Human Health U.S. Laboratories Chief Medical Officer Peter Dannenbaum VP, Investor Relations 24
Slide 25: Appendix
INVENTING FOR LIFE Appendix
Slide 26: Financial Overview: Deal Terms
Financial Overview Deal Terms • Daiichi Sankyo and Merck have entered into a global development and commercialization agreement for patritumab deruxtecan, Focus ifinatamab deruxtecan and raludotatug deruxtecan. • Co-develop and co-commercialize the three ADCs on a worldwide basis (except Japan). • M
Slide 27: Acronyms
Acronyms ADC = Antibody-drug conjugate INT = Individualized neoantigen therapy NSCLC = Non-small cell lung cancer BTK = Bruton’s tyrosine kinase ITT = Intent to treat ORR = Objective response rate CI = Confidence Interval HCC = Hepatocellular carcinoma OS = Overall survival cSCC = Cutaneous squamous
Slide 28: Dean Li, M.D., Ph.D.
Dean Li, M.D., Ph.D. President, Merck Research Laboratories Dr. Dean Li serves as executive vice president and president of Merck Research Laboratories. He leads the company’s worldwide human vaccines and therapeutics research and development organization. Since joining Merck in 2017, Dean has held
Slide 29: Eliav Barr, M.D.
Eliav Barr, M.D. Senior Vice President Head of Global Clinical Development, Chief Medical Officer Dr. Eliav Barr is senior vice president and head of Global Clinical Development and Chief Medical Officer at Merck Research Laboratories. He leads all late-stage clinical development for Merck’s human h
Slide 30: Marjorie Green, M.D.
Marjorie Green, M.D. Senior Vice President Head of Late-Stage Oncology, Global Clinical Development Dr. Marjorie Green is senior vice president and head of late-stage oncology at Merck Research Laboratories. She leads all late-stage clinical development programs for oncology. Marjorie joins Merck fr
Slide 31: Jannie Oosthuizen
Jannie Oosthuizen President, Human Health U.S. Jannie Oosthuizen leads Merck Human Health U.S., which is Merck’s largest business globally. He is responsible for P&L, strategy, customer engagement and commercialization in the U.S. for Merck’s broad portfolio of human health medicines and vaccines. J